Dorsal-to-ventral shift in midbrain dopaminergic projections and increased thalamic/raphe serotonergic function in early Parkinson disease

Journal of Nuclear Medicine

Volumn 56, Issue 7, 2015, Pages 1036-1041

  Joutsa, Juho ^a   Johansson, Jarkko ^a   Sepp¨en, Marko ^a   Noponen, Tommi ^a   Kaasinen, Valtteri ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Dopamine; Midbrain; Raphe nuclei; Serotonin; SPECT

Indexed keywords

N OMEGA FLUOROPROPYL 2BETA CARBOMETHOXY 3BETA (4 IODOPHENYL)NORTROPANE I 123; NEUROLEPTIC AGENT; RADIOPHARMACEUTICAL AGENT; SEROTONIN; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG; 2-CARBOMETHOXY-8-(3-FLUOROPROPYL)-3-(4-IODOPHENYL)TROPANE; DOPAMINE; LIGAND; RADIOACTIVE IODINE; TROPANE DERIVATIVE;

AGED; ARTICLE; CAUDATE NUCLEUS; CINGULATE GYRUS; CONTROLLED STUDY; CORPUS STRIATUM; DIAGNOSTIC IMAGING; DOPAMINERGIC TRANSMISSION; DRUG BINDING; DRUG UPTAKE; DRUG USE; FEMALE; HUMAN; INSULA; MAJOR CLINICAL STUDY; MALE; MESENCEPHALON; NIGRONEOSTRIATAL SYSTEM; PARKINSON DISEASE; PREFRONTAL CORTEX; PRIORITY JOURNAL; PUTAMEN; RAPHE NUCLEUS; SEROTONINERGIC TRANSMISSION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THALAMUS NUCLEUS; TREMOR; VOXEL BASED MORPHOMETRY; CASE CONTROL STUDY; CHEMISTRY; COMPUTER ASSISTED TOMOGRAPHY; FOLLOW UP; IMAGE PROCESSING; MIDDLE AGED; RETROSPECTIVE STUDY; SCINTISCANNING; THALAMUS;

AGED; CASE-CONTROL STUDIES; DOPAMINE; FOLLOW-UP STUDIES; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IODINE RADIOISOTOPES; LIGANDS; MALE; MESENCEPHALON; MIDDLE AGED; PARKINSON DISEASE; RAPHE NUCLEI; RETROSPECTIVE STUDIES; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; THALAMUS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TOMOGRAPHY, X-RAY COMPUTED; TROPANES;

EID: 84936759501     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.153734     Document Type: Article

References (39)

1. Braak H, Del Tredici K, Rüb U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24:197-211.
2. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain. 1991;114:2283-2301.
3. Nandhagopal R, Kuramoto L, Schulzer M, et al. Longitudinal progression of sporadic Parkinson's disease: A multi-tracer positron emission tomography study. Brain. 2009;132:2970-2979.
4. Weintraub D, Koester J, Potenza M, et al. Impulse control disorders in Parkinson disease: A cross-sectional study of 3090 patients. Arch Neurol. 2010;67:589-595.
5. Steeves TD, Miyasaki J, Zurowski M, et al. Increased striatal dopamine release in Parkinsonian patients with pathological gambling: A [11C] raclopride PET study. Brain. 2009;132:1376-1385.
6. O'Sullivan SS, Wu K, Politis M, et al. Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours. Brain. 2011;134:969-978.
7. Joutsa J, Martikainen K, Niemelä S, et al. Increased medial orbitofrontal [18F]fluorodopa uptake in Parkinsonian impulse control disorders. Mov Disord. 2012;27:778-782.
8. Gotham AM, Brown RG, Marsden CD. 'Frontal' cognitive function in patients with Parkinson's disease 'on' and 'off' levodopa. Brain. 1988;111:299-321.
9. Vaillancourt DE, Schonfeld D, Kwak Y, Bohnen NI, Seidler R. Dopamine overdose hypothesis: evidence and clinical implications. Mov Disord. 2013;28:1920-1929.
10. Kraemmer J, Kovacs GG, Perju-Dumbrava L, Pirker S, Traub-Weidinger T, Pirker W. Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts. Mov Disord. 2014;29:1767-1773.
11. Scheffel U, Lever JR, Abraham P, et al. N-substituted phenyltropanes as in vivo binding ligands for rapid imaging studies of the dopamine transporter. Synapse. 1997;25:345-349.
12. Koch W, Unterrainer M, Xiong G, et al. Extrastriatal binding of [123I]FP-CIT in the thalamus and pons: gender and age dependencies assessed in a European multicentre database of healthy controls. Eur J Nucl Med Mol Imaging. 2014;41: 1938-1946.
13. Kim SE, Choi JY, Choe YS, Choi Y, Lee WY. Serotonin transporters in the midbrain of Parkinson's disease patients: A study with 123I-beta-CIT SPECT. J Nucl Med. 2003;44:870-876.
14. Isaias IU, Marzegan A, Pezzoli G, et al. A role for locus coeruleus in Parkinson tremor. Front Hum Neurosci. 2011;5:179.
15. Isaias IU, Marotta G, Pezzoli G, et al. Enhanced catecholamine transporter binding in the locus coeruleus of patients with early Parkinson disease. BMC Neurol. 2011;11:88.
16. Roselli F, Pisciotta NM, Pennelli M, et al. Midbrain SERT in degenerative parkinsonisms: A 123I-FP-CIT SPECT study. Mov Disord. 2010;25:1853-1859.
17. Caretti V, Stoffers D, Winogrodzka A, et al. Loss of thalamic serotonin transporters in early drug-naïve Parkinson's disease patients is associated with tremor: an [123I]b-CIT SPECT study. J Neural Transm. 2008;115:721-729.
18. Kaasinen V, Kinos M, Joutsa J, Seppänen M, Noponen T. Differences in striatal dopamine transporter density between tremor dominant and non-tremor Parkinson's disease. Eur J Nucl Med Mol Imaging. 2014;41:1931-1937.
19. Darcourt J, Booij J, Tatsch K, et al. EANM procedure guidelines for brain neurotransmission SPECT using 123I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging. 2010;37:443-450.
20. Ashburner J. A fast diffeomorphic image registration algorithm. Neuroimage. 2007;38:95-113.
21. Maldjian JA, Laurienti PJ, Kraft RA, Burdette JH. An automated method for neuroanatomic and cytoarchitectonic atlas-based interrogation of fMRI data sets. Neuroimage. 2003;19:1233-1239.
22. de la Riva P, Smith K, Xie SX, Weintraub D. Course of psychiatric symptoms and global cognition in early Parkinson disease. Neurology. 2014;83:1096-1103.
23. Todorova A, Jenner P, Ray Chaudhuri K. Non-motor Parkinson's: integral to motor Parkinson's, yet often neglected. Pract Neurol. 2014;14:310-322.
24. Lee JY, Seo SH, Kim YK, et al. Extrastriatal dopaminergic changes in Parkinson's disease patients with impulse control disorders. J Neurol Neurosurg Psychiatry. 2014;85:23-30.
25. Cilia R, van Eimeren T. Impulse control disorders in Parkinson's disease: seeking a roadmap toward a better understanding. Brain Struct Funct. 2011;216:289-299.
26. García-Cabezas MA, Rico B, Sánchez-González MA, Cavada C. Distribution of the dopamine innervation in the macaque and human thalamus. Neuroimage. 2007;34:965-984.
27. Hawkes CH, Del Tredici K, Braak H. A timeline for Parkinson's disease. Parkinsonism Relat Disord. 2010;16:79-84.
28. Miguelez C, Morera-Herreras T, Torrecilla M, Ruiz-Ortega JA, Ugedo L. Interaction between the 5-HT system and the basal ganglia: functional implication and therapeutic perspective in Parkinson's disease. Front Neural Circuits. 2014; 8:21.
29. Balcioglu A, Zhang K, Tarazi FI. Dopamine depletion abolishes apomorphine-and amphetamine-induced increases in extracellular serotonin levels in the striatum of conscious rats: A microdialysis study. Neuroscience. 2003;119:1045-1053.
30. Rozas G, Liste I, Guerra MJ, Labandeira-Garcia JL. Sprouting of the serotonergic afferents into striatum after selective lesion of the dopaminergic system by MPTP in adult mice. Neurosci Lett. 1998;245:151-154.
31. Prinz A, Selesnew LM, Liss B, Roeper J, Carlsson T. Increased excitability in serotonin neurons in the dorsal raphe nucleus in the 6-OHDA mouse model of Parkinson's disease. Exp Neurol. 2013;248:236-245.
32. Politis M, Wu K, Loane C, et al. Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study. Neurobiol Dis. 2010;40:216-221.
33. Kaasinen V, Ruottinen HM, Nagren K, Lehikoinen P, Oikonen V, Rinne JO. Upregulation of putaminal dopamine D2 receptors in early Parkinson's disease: A comparative PET study with [11C]raclopride and [11C]N-methylspiperone. J Nucl Med. 2000;41:65-70.
34. Rinne UK, Laihinen A, Rinne JO, Nagren K, Bergman J, Ruotsalainen U. Positron emission tomography demonstrates dopamine D2 receptor supersensitivity in the striatum of patients with early Parkinson's disease. Mov Disord. 1990; 5:55-59.
35. Politis M, Niccolini F. Serotonin in Parkinson's disease. Behav Brain Res. 2015;277:136-145.
36. Huot P, Fox SH. The serotonergic system in motor and non-motor manifestations of Parkinson's disease. Exp Brain Res. 2013;230:463-476.
37. Boileau I, Warsh JJ, Guttman M, et al. Elevated serotonin transporter binding in depressed patients with Parkinson's disease: A preliminary PET study with [11C] DASB. Mov Disord. 2008;23:1776-1780.
38. Politis M, Wu K, Loane C, et al. Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures. Neurology. 2010;75:1920-1927.
39. Leentjens AF, Van den Akker M, Metsemakers JF, Lousberg R, Verhey FR. Higher incidence of depression preceding the onset of Parkinson's disease: A register study. Mov Disord. 2003;18:414-418.